(Q53545686)

15 May 2018

title

Platelet to lymphocyte ratio as a new prognostic for patients with metastatic renal cell cancer. (English)

1 reference

15 May 2018

0 references

Seyda Gunduz

1

1 reference

15 May 2018

Hasan Mutlu

2

1 reference

15 May 2018

Deniz Tural

3

1 reference

15 May 2018

Özcan Yıldız

4

1 reference

15 May 2018

Mukremin Uysal

5

1 reference

15 May 2018

Hasan Senol Coskun

6

1 reference

15 May 2018

Hakan Bozcuk

7

1 reference

15 May 2018

publication date

14 April 2015

1 reference

15 May 2018

Asia Pacific Journal of Clinical Oncology

published in

1 reference

15 May 2018

volume

11

1 reference

15 May 2018

issue

4

1 reference

15 May 2018

page(s)

288-292

1 reference

15 May 2018

Survival and prognostic stratification of 670 patients with advanced renal cell carcinoma.

cites work

1 reference

https://api.crossref.org/works/10.1111%2FAJCO.12358

21 January 2018

Inflammation and cancer

1 reference

https://api.crossref.org/works/10.1111%2FAJCO.12358

Platelets, inflammation and tissue regeneration

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FAJCO.12358

21 January 2018

The platelet-cancer loop

1 reference

https://api.crossref.org/works/10.1111%2FAJCO.12358

Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: results from a large, multicenter study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FAJCO.12358

Platelet to lymphocyte ratio as a prognostic factor for epithelial ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FAJCO.12358

Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FAJCO.12358

Antiangiogenic therapy for advanced renal cell carcinoma: management of treatment-related toxicities

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FAJCO.12358

Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FAJCO.12358

Sorafenib for treatment of renal cell carcinoma: Final efficacy and safety results of the phase III treatment approaches in renal cancer global evaluation trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FAJCO.12358

21 January 2018

Identifiers

DOI

10.1111/AJCO.12358

1 reference

15 May 2018

1 reference

15 May 2018